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Abstract: Membrane processes are used extensively in biomedical applications. This state of the art review presents the 
main applications including renal kidney, blood filtration, blood oxygenator, artificial liver, artificial pancreas, and drug 
delivery devices. For well-established treatments like dialysis, plasmapheresis, and blood oxygenator, the techniques are 
summarized by presenting membranes used, devices, configurations and treatments. The artificial liver and the artificial 
pancreas are not clinically used and some main aspects related to the development of these devices are given, including 
configurations and liver or pancreatic cells. Finally, drug delivery devices based on membranes, which are an important 
area in pharmaceutics, are summarized by focusing on diffusion and transdermal delivery systems, as well as colloids 
like liposomes and nanocapsules. These colloids with nanometric size are surrounded by a lipidic or polymeric thin 
membrane which controls drug transfer to the surrounding medium. 
Keywords: Membrane processes, Biomedical applications, Bioartificial organs, Dialysis, Blood oxygenator, Drug 
delivery. 
1. INTRODUCTION 
Biomedical membrane processes are among the 
first successful membrane techniques [1, 2]. They 
include biomedical techniques like renal kidney, blood 
filtration, blood oxygenation, artificial liver, artificial 
pancreas, and drug delivery devices. Among these 
techniques, dialysis, plasmapheresis, and blood 
oxygenation are routine clinical treatment. Dialysis is 
defined as the diffusion of molecules in solution across 
a semipermeable membrane along an electrochemical 
concentration gradient [3-5]. Over the past half century, 
the widespread use of dialysis to prolong life for people 
without kidney function has been a remarkable 
achievement. Plasmapheresis, or plasma exchange, is 
an extracorporeal blood-purification process whereby 
plasma is removed from the patient and artificially 
replaced [6, 7]. It is widely used to remove large 
molecular weight pathogens from the patient’s blood, 
including antibodies, immune complexes, monoclonal 
proteins, endotoxins, drugs, and cholesterol containing 
lipoproteins. The last technique, the membrane blood 
oxygenation is clinically used to oxygenate the patient’s 
blood during open-heart surgery [8]. Gas (usually 
oxygen or oxygen/nitrogen mixtures) diffuses from the 
gas phase through the gas-filled membrane pores into 
the blood, and carbon dioxide diffuses from the blood 
into the gas for disposal.  
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Bioartifical organs, like artificial liver and bioartificial 
pancreas have also been extensively studied, although 
their applications remain more limited. Artificial liver 
systems have been developed to bridge patients with 
severe liver failure to liver transplantation or liver 
regeneration [9-11]. These devices include artificial 
organs, based on hemodialysis, plasmapheresis, 
specific or non-specific adsorption, and bioartificial 
organs. Bioartificial pancreases are dedicated to the 
treatment of diabetes which represents a major public 
health problem in industrialized countries [12, 13]. 
Three major types of bioartificial pancreas have been 
developed: diffusion chamber, hollow fiber unit and 
microcapsules. 
Finally, drug delivery systems enable the 
introduction of a therapeutic substance in the body and 
improve its efficacy and safety by controlling the rate, 
time, and place of its release. Drug delivery systems 
are commercialized in various forms and applied to 
various medical treatments. Drug delivery membrane 
systems include osmotic membrane systems, diffusion 
controlled membrane systems (pills, implants, 
patches), and transdermal drug delivery [1, 2]. 
Liposomes and nano and microcapsules, which are 
spherical shaped colloids, may also be considered as 
membrane drug delivery systems, as their aqueous 
core is surrounded by a lipidic or polymeric membrane.  
In this state of the art review, we focused on 
medical applications of artificial membranes including 
artificial organs and drug delivery systems based on 
membranes. Several membrane artificial organs are 
described in detail: artificial kidney, blood oxygenation, 
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artificial liver, and artificial pancreas. For drug delivery, 
diffusion controlled systems include pills, implants and 
patches; and transdermal delivery systems include 
passive as well as iontophoretic systems. Colloidal 
formulation are also detailed such as liposomes [14-16] 
and nanocapsules [17, 18] with a lipidic or polymeric 
membrane surrounding an aqueous core. 
2. DIALYSIS - ARTIFICIAL KIDNEY  
Several reviews on specific aspects related to 
dialysis and artificial kidney are available. For example, 
Himmelfarb and Ikizler [3] describe the medical, social, 
and economic evolution of hemodialysis therapy. 
Treatment time, frequency of dialysis, hemodialysis in 
the United States, patient safety and technical 
advances, controlled trials of dialysis therapy and 
evaluation of cardiovascular risk are detailed. Hoenich 
[19] presents the current state of the art of 
hemodialysis membranes and discuss their biocompati- 
bility and the role played in morbidity and mortality 
associated with dialysis treatment. Ronco et al. [4] 
analysed the evolution of synthetic membranes for 
blood purification, by focusing on Polyflux membranes, 
originally derived from polyamide. Waniewski [5] 
described current approaches to modeling of transport 
processes in dialysis, including the urea model, sodium 
model, models of peritoneal transport, which combine 
the general physiological knowledge with information 
about individual patients yielded by clinical 
measurements. Alternative and complementary appro- 
aches to modeling of transport processes in dialysis 
are also discussed.  
Hemodialysis 
In hemodialysis, dialysis is applied to blood 
purification of patients with end-stage renal disease. 
The primary goal of hemodialysis is to restore the 
intracellular and extracellular fluid environment that is 
characteristic of normal kidney function [3]. By 
replacing kidney excretory function, dialysis is intended 
to eliminate the symptom complex known as the uremic 
syndrome. Hemodialysis is accomplished by the 
transport of solutes such as urea, creatinine, and 
glucose from the blood into the dialysate and by the 
transport of solutes such as bicarbonate from the 
dialysate into the blood. Solute concentration and 
molecular weight are the primary determinants of 
diffusion rates. Small molecules, such as urea, diffuse 
quickly, whereas larger molecules, such as phosphate, 
β2-microglobulin, and albumin, and protein bound 
solutes diffuse much more slowly. In addition to 
diffusion, solutes may pass through pores in the 
membrane by means of a convective process driven by 
hydrostatic or osmotic pressure gradients. 
The usual hemodialysis treatment time is about 4 h 
and frequency is 2 or 3 times per week [3]. The blood 
flow rate is usually between 200 to 400 mL/min, and 
depends on the type and quality of vascular access. 
Increasing blood flow increases solute removal; 
however, increased flow resistance will eventually limit 
the augmented clearance. The usual dialysate flow rate 
is twice the blood flow rate in order to obtain optimal 
solute clearance. The dialysate is typically composed 
of sodium, potassium, calcium, magnesium, alkaline 
buffers, predominantly bicarbonate with a small amount 
of acetate, chloride defined by prescribed cations and 
alkaline buffers in dialysate, glucose, and anticoagula- 
tion heparin or other agents. 
Hemofiltration and Hemodiafiltration 
Different other modes of dialysis treatment are 
commonly used. Hemofiltration is a fully convective 
treatment in which large amounts of ultrafiltrate are 
produced and replaced by an ultrapure substitution 
fluid, and no dialysis fluid is present [4]. This treatment 
offers the advantage of excellent clearances for large 
molecules. However, it has only been clinically applied 
in Europe because of the need for large quantities of 
substitution fluids and their high costs. 
Hemodiafiltration is a treatment in which diffusive 
and convective transport occurs simultaneously [4]. 
The amount of ultrafiltration exceeds the patient weight 
loss, and therefore the final fluid balance is achieved by 
the infusion of appropriate amounts of substitution fluid 
in the arterial or venous line. Due to high costs related 
to substitution fluids, new approaches have been 
proposed in Europe for performing hemofiltration and 
hemodiafiltration. Part of the fresh dialysate is diverted 
from its line to the dialyser, is filtered and used as an 
ultrapure substitution fluid. These on-line treatments 
have the advantage of reduced costs, unlimited 
production of substitution fluid and no need for 
commercially prepared fluids in bags. The 
microbiological and chemical purity of the on-line 
produced fluid have been proved to be sufficient. 
Dialysis Membranes 
Cellulose and its derivatives are the first generation 
of polymers which were used in dialyzers in the 1970s. 
However, the low membrane permeability and 
molecular weight cutoff near 2000 daltons of cellulose-
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based materials limits their use. From the 1980s, 
synthetic polymers such as polysulfone, 
polyethersulfone, polyacrylonitrile, polyamide and 
polymethylmethacrylate have been widely developed 
and can be considered as the second generation of 
dialysis membranes. Compared to cellulose mem- 
brane, synthetic materials offer a higher permeability 
and can be tailored to different molecular weight 
cutoffs. However, the hydrophobicity of synthetic 
polymer has adverse effect on biocompatibility. 
Therefore, surface grafting, coating or blending are 
usually needed to render the membrane hydrophilic 
and improve biocompatibility.  
The Polyflux membranes are examples of dialysis 
membranes made from polymers blend, originally 
derived from the synthetic polymer polyamide (Figure 
1) [4]. Three different polymers are used: polyamide, 
which provides endotoxin retention due to the 
hydrophobic sites and improved biocompatibility due to 
minimal interaction with blood components; 
polyarylethersulfone, which provides mechanical 
strength and resistance to heat sterilization; and 
polyvinylpyrrolidone frequently used in pharmaceutical 
formulations, which contributes to the hydrophilic 
domains in the surface and the enhanced diffusive 
permeability.  
Characteristics of membranes used in dialyzers 
include water flux or water permeability. The water 
permeability of hemodialysis membranes is typically 
obtained from experiments in which bovine blood is 
ultrafiltered at varying transmembrane pressures 
(TMP). The relationship between plasma ultrafiltration 
rate and TMP is linear at relatively low TMP values, 
whereas a plateau occurs at higher TMP values. The 
permeability is defined by the slope of the linear portion 
of the permeate rate versus TMP curve. Low-flux 
dialysis favoring the removal of low-molecular-weight 
solutes may be performed using membranes 
manufactured from cellulose, modified cellulose, or 
synthetic polymer blends. Hemodiafiltration or 
hemofiltration require the use of high flux membranes, 
predominantly manufactured from synthetic materials. 
High-flux dialysis offering enhanced removal of small 
molecules and reduced treatment times (when used in 
combination with high blood and dialysate flow rates) 
can be performed with modified cellulose or synthetic 
membranes. In this case, convective transport 
dominates. 
Biocompatibility related to the repeated contact of 
blood of patients treated by dialysis in the 
extracorporeal circuit is an important clinical issue [19]. 
The membrane in a dialyzer represents a large non-
physiologic surface to which the blood is exposed 
during each treatment. This exposure results in a 
number of events such as the deposition of proteins 
onto the membrane surface, activation of the 
complement system, kinin, and coagulation and 
fibrinolytic pathways, as well as activation of the 
cellular elements of blood on each occasion (Figure 2). 
A variety of factors governs the magnitude of these 
events, including chemical composition and surface 
character, with synthetic materials outperforming 
cellulose-based materials. However, it remains unclear 
if membrane biocompatibility may have a role in patient 
survival and recovery of renal function in acute renal 
failure. There seems to have no association between 
membrane type and recovery of renal function and that 
factors other than the membrane such as comorbid 
conditions and dose of dialysis are more important [19]. 
Membrane Modules 
The first dialysis modules were flat plate- and 
frame-modules and coil type modules [1]. The flat 
plate-and frame-modules contained sheets of 
cellophane or cuprophane membranes. The coil type 
modules consisted of cellophane tubes, which were 
flattened, placed on a nylon open mesh “spacer” 
material and rolled into a coil. The coil was then held in 
a cartridge which was open at each end. Today, most 
dialysis modules are in hollow fiber configuration 
 
Figure 1: The Polyflux membrane results from a blend of chemical components prevalently present in the different layers of the 
membrane wall. (redrawn from [4]).  
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modules. The fiber length is approximately 30 cm and 
the modules contain thousands of fibers (up to 15,000, 
membrane surface area up to 2.2 m2). The inner 
diameter is typically between 180 and 220 µm and wall 
thickness between 20 and 50 µm.  
The design and the construction of the dialysate 
compartment are of major importance for the 
performance of a dialyser to ensure even distribution of 
the dialysate [1]. For this purpose, different 
configurations have been proposed such as spacer 
yarns, fiber crossing or waved fibers. The wavy shape 
of the undulated fiber prevents dense packing and 
ensures optimum dialysate circulation. In the Polyflux 
dialysers, waved fibres are additionally crossed and, by 
combining these two steps, a three-dimensional 
network guarantees stable and high mass transport 
rates in the whole bundle [4]. A homogeneous 
distribution of the flow can then achieved as well as a 
significant increase in solute clearances. In addition, 
the blood ports cannot be considered simply as arterial 
and venous ends of the unit [4]. They must have a 
minimal stagnation of flow and should guarantee a 
homogeneous distribution of blood flow in all the fibres 
of the bundle. For this purpose, different types of flow 
distributors have been proposed (conical, spiral, etc.) 
with reduced space between the cap and the potting. 
Urea Kinetic Modeling 
Several models has been proposed for solute 
transport in hemodialyzer which have been extensively 
reviewed [5]. For example, the solute flows in blood 
and dialysate channels can been obtained by using the 
mass balance in the slice from x to x+d of the 
membrane [20]. Urea is usually used for quantifying 
dialysis adequacy through mathematical modelling 
based on changing blood concentrations [3, 5]. The 
most well-known parameter is “Kt/V”, an index of small 
solute (like urea) removal. It was introduced in the 
1970s, and then linked to the morbidity and mortality of 
hemodialysis patients based on the results of the 
National Cooperative Dialysis Study [21]. From the 
1990s, it was increasingly used and investigated in 
many studies. 
In human kidney and dialyzer, waste solute removal 
is proportional to solute concentration [22]. In the 
steady state when mass of solute is constant, the 
generation and removal rates are equal. The 
mathematical description of the balance of total urea 
mass is given by: 
 0 = G ! KrC             (1) 
where G is generation rate (mg/min), Kr is renal 
clearance (ml/min), and C is concentration (mg/mL). 
Eq. 1 can be solved as: 
C = G /Kr            (2) 
Eq. 2 describes the relationship between genera- 
tion, clearance and concentration for many solutes 
excreted by the human kidney. When steady state is 
not more realized, such as in intermittent dialysis 
therapy, the mass balance is written as the product of 
solute distribution volume (V) and rate of change in 
concentration (dC/dt): 
 
Figure 2: Blood pathway activation following material contact (redrawn from [19]). 
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V (dC / dt) = G ! KdC ! KrC          (3) 
where Kd is the intermittent dialyzer clearance and Kr is 
the remaining continuous renal clearance. Integration 
of eq. 3 over a complete treatment gives: 
 Ct = C0 exp(!Kdt /V ) + (G /Kr )(1! exp(!Kdt /V ))        (4) 
where C0 and Ct are the initial and final solute 
concentrations at the beginning and end of each 
dialysis. 
Eq. 4 can be applied to any solute targeted for 
removal and concentration control by intermittent 
dialysis therapy [22]. In Eq. 4, Kdt/V is an exponential 
term which controls the magnitude of drop in solute 
concentration over a complete dialysis treatment. It 
quantifies the mechanisms by which solute removal is 
achieved by either dialyzer clearance or renal 
clearance; the concentration of solute being a function 
of both Kdt/V and the generation rate, G. Nowadays, 
Kdt/V is the basic parameter to prescribe the dose of 
dialysis (clearance Kd, time of dialysis t) for patients, 
represented by their total body water volume V. The 
clearance depends on the hemodialyzer used and 
operating conditions of dialysis (blood and dialysate 
flows, ultrafiltration rate) and it can be predicted from a 
mathematical model of dialyzer performance [5]. 
Several models have been derived from the simple 
Kt/V model, such as spKt/V, eKt/V, (Kt/V)dp, of single-
pool, effective and double-pool Kt/V model, 
respectively [23]. Nevertheless, it has been pointed out 
that Kt/V and associated parameters should not be the 
only ones to be taken into account for the assessment 
of dialysis adequacy based on small solute removal. 
Many clinicians demonstrated that the dose parameter 
must be associated with medical outcome, e.g. 
mortality, morbidity, or medical well-being.  
Several models has been proposed for solute 
transport in hemodialyzer which have been extensively 
reviewed [5]. For example, the solute flows in blood 
and dialysate channels can been obtained by using the 
mass balance in the slice from x to x+d of the 
membrane [20]. 
3. PLASMAPHERESIS 
This state of the art review focuses on therapeutic 
plasmapheresis as a medical treatment, although 
plasmapheresis can also be conducted as donor 
plasmapheresis. Therapeutic plasmapheresis has been 
reviewed extensively. For example, Nakanishi et al. [6] 
described the state of the art of various therapeutic 
plasmapheresis (plasmapheresis with addition of a 
substitution fluid, double-filtration plasmapheresis 
(DFPP), and plasma adsorption) by presenting their 
modalities, representative diseases, and complications. 
Baweja et al. [7] reviewed current indications of 
plasmapheresis, or plasma exchange, for treatment in 
renal disease, such as anti-glomerular basement mem- 
brane disease, cryoglobulinemia, multiple myeloma, 
and in case of some renal transplantation.  
Plasma Exchange 
Plasmapheresis, or plasma exchange, is an 
extracorporeal blood-purification process whereby 
plasma is removed from the patient and artificially 
replaced [7]. The process was first described in the dog 
in 1914 and the first therapeutic plasmapheresis was 
performed in two patients with macroglobulinemia in 
the 60’s. Since then, it has been widely used to remove 
large molecular weight pathogens from the patient’s 
blood, including antibodies, immune complexes, 
monoclonal proteins, endotoxins, drugs, and 
cholesterol containing lipoproteins.  
Several plasmapheresis techniques are currently 
available, such as plasma exchange, DFPP, and 
plasma adsorption [6]. Each modality has its own 
advantages and disadvantages based on the efficacy 
and specificity of removing the target substance, cost, 
and complications. Plasma exchange was developed in 
the 1970s and is currently widely used. In this 
treatment, the whole plasma is discarded using a 
plasma separator, which contains essential and 
pathogenic substances, and the substitution fluid of 
equal volume to the discarded plasma is infused back 
to the patient. Plasma exchange is used to treat many 
diseases, such as thrombotic microangiopathy, hepatic 
failure, and neurological diseases. In addition to the 
removal of pathogenic substances, essential factors, 
such as albumin and coagulation factors can be 
supplied to the patient. The whole blood flows into a 
plasma separator and approximately 0.6-1.2 L/h of 
plasma is separated from the whole blood for 3-4 h. 
Usually, the substitution fluid is fresh frozen plasma or 
4–6 % albumin solution, depending on the coagulation 
and/or immune state of the patient. 
Double Filtration Plasmapheresis 
The principle of DFPP was first introduced by Agishi 
et al. [24] to reduce the amount of substitution fluid, 
such as albumin solution. Two types of membrane 
filters with different pore sizes are used for DFPP: the 
plasma separator and the plasma fractionator with 
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smaller pore size. The plasma separator separates 
plasma from the whole blood, while the plasma 
fractionator fractionates the smaller molecular 
substances, including albumin, from relatively higher 
molecular weight (MW) proteins, such as 
immunoglobulins, associated with the pathogenesis of 
the disease. The albumin-rich plasma, filtered with the 
plasma fractionator, is returned to the patient with the 
substitution fluid to maintain the plasma volume. Thus, 
DFPP can selectively remove macromolecules and 
reduce the use of substitution fluid, compared to 
plasmapheresis in the plasma exchange configuration. 
DFPP is mainly used for conditions in which relatively 
larger molecules in the plasma are responsible for the 
pathogenesis (e.g., hyperviscosity syndrome and 
several neurological diseases) [6]. Furthermore, DFPP 
has been used to remove antibodies due to blood 
group ABO-incompatible kidney transplantation.  
Several types of plasma fractionators are available 
for adequate removal of the targeted substance with a 
more specific MW depending on the specificity of the 
pathogens in each disease [6]. The membrane of the 
plasma fractionator has a microporous structure similar 
to the membranes used for plasma separation, but the 
pore size is 0.01–0.03 µm compared to the plasma 
separator, which is 0.3 µm. Therefore, the pore size of 
the plasma fractionator should be selected according to 
the MW of the target substance. The Cascadeflo EC-
20w or EC-30w (Asahi-Kasei Medical Co., Ltd., Tokyo, 
Japan) is designed for removing immunoglobulin G 
(IgG) and/or immunoglobulin A (IgA), the EC-40w is 
used for removing immunoglobulin (IgM) and/or 
macroglobulin, and the EC-50w is used for removing 
low-density lipoprotein and/or hepatitis C virus. The 
Cascadeflo devices contain ethylene vinyl alcohol 
copolymer hollow fibers. The inside diameter is 175 
µm, with overall dimensions of 280 mm (length) and 57 
mm (diameter) which gives a total surface area of 2.0 
m2. 
A common complication of plasmapheresis using 
membrane filtration is hemolysis [25], especially in 
DFPP and occurs in approximately 20% of the 
treatments. Hemolysis often causes early termination 
of the treatment. It is usually attributed to increased 
TMP, which causes alteration in the plasma flow, 
shearing forces, and sieving. 
Plasma Adsorption 
The third technique, plasma adsorption, can 
specifically remove pathogenic agents, such as 
autoantibodies, immune complexes, low density 
lipoprotein (LDL), and bilirubin, from the plasma using 
an adsorption column with selectivity for each 
substance [6]. Plasma adsorption does not require 
substitution fluids because of its minimal loss of 
essential plasma proteins. Therefore, the advantage is 
the lower risk of an anaphylactic reaction or viral 
infection compared to plasma exchange and DFPP. 
Plasma adsorption includes LDL-apheresis, 
immunoadsorption plasmapheresis, and bilirubin 
apheresis. Several plasma adsorption columns are 
available such as the Immusorba TR and PH, Plasorba 
BRS (Asahi Kasei Medical, Japan), Liposorber LA and 
Selesorb (Kaneka Medix, Japan), and Medisorba BL 
(Kawasumi, Japan) [6]. For example, the 
immunoadsorption column of the Immusorba TR device 
contains 300 mL of a tryptophan immobilized 
polyvinylalcohol gel and is designed specifically for the 
treatment of neurological diseases; the Immusorba TR 
device is made from 300 mL of phenylalanine 
immobilized polyvinylalcohol gel for treatment of 
autoimmune diseases (e.g. systemic lupus 
erythematosus, malignant rheumatoid arthritis, Guillain-
Barré syndrome, chronic inflammatory demyelinating 
polyneuropathy, multiple sclerosis). 
Plasma adsorption can also be realized using 
affinity membranes instead of adsorption columns. 
Affinity membranes exhibit short treatment time and 
excellent selectivity for toxins due to elimination of 
diffusional resistance and high specific binding. They 
have been introduced in the 1980’s [26] and then used 
to remove successfully pathogenic agents such as 
antibodies, bilirubin and endotoxin. The removal of 
bilirubin and endotoxin using affinity membranes is 
detailed below. 
Bilirubin, one of the common metabolites of 
hemoglobin, is a pathogenic substance which is 
released into blood due to the normal or abnormal 
destruction of red blood cells. At high bilirubin 
concentration, jaundice occurs, indicating hepatic or 
biliary tract dysfunction. High bilirubin concentration in 
blood (i.e. hyperbilirubinemia) may also cause brain 
damage or death in more severe cases. Several affinity 
membranes have been proposed for bilirubin removal. 
For example, arginine as model ligand for affinity 
adsorption of bilirubin was immobilized on a composite 
membrane to obtain arginine-immobilized affinity 
membrane, to remove bilirubin from plasma [27].  
Endotoxin, the lipopolysaccharide (LPS) component 
of the outer cell wall of Gram-negative bacteria, 
produces serious biological effects when it enters into 
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the human blood system, even at extremely low 
concentration. It is considered as a key factor in the 
pathogenesis of sepsis. Some surface-modified 
hemodialysis hollow fiber membranes have been 
reported to have ability to remove LPS from blood. For 
example, Zhang et al. [28] proposed affinity membrane 
modules for extracorporeal elimination of endotoxin 
from blood by grafting l-serine ligand onto 
polyvinylidene fluoride (PVDF) hollow fiber 
membranes. The affinity membranes were then used to 
remove endotoxin from sepsis patients’ plasma in vitro. 
At an initial concentration of 0.42 EU/mL, the endotoxin 
adsorption capability was 0.058 EU/cm2 and the 
removal efficiency was almost 100% for 15 mL, 93.5% 
and 48.3% for 20 mL and 40 mL samples, respectively.  
Affinity membranes have been proved to be 
successful for plasma treatment in vitro, as shown in 
the two examples detailed above. However, to our 
knowledge, treatments coupling plasmapheresis to 
membrane adsorption have not been applied clinically. 
4. STEM CELLS PURIFICATION 
In clinical applications, stem cell therapy is a 
promising technology in which the target cells are 
recovered and purified from autologous or allogenic 
sources [29]. The cells are then cultured in vitro or 
directly transplanted to regenerate damaged or 
impaired tissue. Stem cell therapies have been applied 
to the treatment of several pathologies like 
musculoskeletal, hematopoietic, neurological, and 
cardiovascular disorders. The separation and 
purification of stem cells exploits the characteristics of 
the cells, which include size, density and surface 
properties (i.e. charge, markers and adhesiveness). 
Purification techniques may be classified into three 
main categories: centrifugation, which is based in size, 
density and adhesiveness properties, immunochemical 
techniques for cell sorting, which require a suitable 
surface marker to use as a tag, and other techniques 
like membrane filtration [29]. 
Membrane filtration is a simple method which does 
not necessitate the use of antibodies targeting stem 
cells. Antibodies are generally produced using animal-
derived proteins and cells, which might cause 
contamination from viruses or prions. For example, 
Higuchi et al. [30] purified hematopoietic stem cells 
(HSCs) from peripheral blood and umbilical cord blood 
by membrane filtration. Different membranes were 
used (e.g. polyurethane foaming membranes and 
Nylon mesh filters) with large pore size of 11 µm. HSCs 
from blood were found to adhere more strongly to 
membranes than red blood cells, platelets, T cells, or B 
cells. Cunha et al. [31] optimized the clarification and 
concentration of human mesenchymal stem cells using 
membrane fibers devices. Human mesenchymal stem 
cells (hMSCs) are expanded using microcarrier-based 
stirred culture systems from one to hundreds of liters of 
culture volume to guarantee the required cell numbers. 
Culture suspension needs then to be clarified, to 
remove microcarriers, and to be concentrated without 
modifying the cells' properties. Polypropylene filters 
with pore sizes higher than 75 µm could ensure the 
removal of microcarriers from the cell suspension bulk, 
without compromising cells' recovery or viability. 
Furthermore, hMSCs were concentrated up to a factor 
of ten, allowing the recovery of more than 80% of 
viable cells, at optimal conditions of initial cell concen- 
tration higher than 2 × 105 cell/mL, and polysulfone 
membranes with pore sizes higher than 0.45 µm  
Specific devices are commercialized for cell 
concentration or dilution, supernatant or culture media 
exchange, and cell washing. For example, in the LOVO 
cell processing system (Fresenius Kabi), a cell solution 
is pumped through a spinning membrane filtration 
device to allow for rapid fluid management and fast, 
efficient cell processing. This spinning membrane 
separation device uses a 4 µm track-etched polycarbo- 
nate membrane, and allows for separation of target 
cells through size discrimination, as well as 
supernatant removal and product concentration or 
dilution. The StemQuickTME system (Asahi Kasei 
Medical, Japan) is a filtration apparatus including a 
filter for collecting white blood cells containing 
hematopoietic stem cells from cord blood [32]. 
5. MEMBRANE BLOOD OXYGENATORS 
Membrane blood oxygenators have been used used 
over 50 years to oxygenate a patient’s blood during 
open-heart surgery [8, 33]. The first membrane blood 
oxygenator was proposed in 1955 by Kolff’s group, 
followed in 1956 by the first disposable membrane 
oxygenator to eliminate the need of cleaning before re-
use. Microporous blood oxygenation has been 
presented in a very complete chapter including history, 
design (flat sheet and hollow fiber, effects of Non-
Newtonian blood rheology, effects of oxygen binding to 
hemoglobin), computational fluid dynamics methods 
and future trends [8]. 
In a membrane blood oxygenator, a microporous 
membrane is used to separate blood and gas phases. 
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Gas (usually oxygen or oxygen/nitrogen mixtures) 
diffuses from the gas phase through the gas-filled 
membrane pores into the blood, and carbon dioxide 
diffuses from the blood into the gas for disposal. 
Hydrophobic flat sheets and hollow fibers can be used. 
The hollow fibers geometry is more popular. A typical 
hollow fibre blood oxygenator (Cobe Optima XP, Cobe 
Cardoivascular Inc., Arvada, USA) contains 14,500 
hollow fibres, with 200 µm inner diameter, 300 µm 
outer diameter, with a total surface area of 1.9 m2. The 
hollow fibres are woven together to form a mat. The 
mats are then wound around a central tube in order to 
form a fibre bundle. Microporous hollow-fiber 
membranes are primarily used for short-term 
cardiopulmonary bypass application, whereas 
nonmicroporous hollow-fiber membranes are used for 
long-term extracorporeal membrane oxgenation.  
Blood oxygenators are designed to include mixing 
of the blood to disrupt the concentration boundary layer 
formed at the membrane surface and thus increase the 
gas-transfer efficiency. In hollow-fiber blood oxygena- 
tors, the blood flows outside and across the fibers 
rather than inside the fibers. Thus the fibers 
themselves induce mixing of the blood. In addition, this 
induces lower pressure resistance in the module and 
causes less hemolysis. In the flat-sheet blood 
oxygenators, a screen is placed in the blood flow 
channel to prevent the flat-sheet membranes from 
collapsing on top of each other. This configuration 
induces also mixing of the blood.  
Since the membranes used are hydrophobic (e.g. 
polypropylene, Teflon), the pores are gas filled 
resulting in a negligible membrane mass transfer 
resistance. The major resistance to oxygen transfer 
from the gas phase to the blood (and carbon dioxide 
transfer in the opposite direction) is due to the blood 
side concentration boundary layer. Several studies 
have focussed on developing mass transfer and friction 
factor correlations for flat sheet and hollow fibre blood 
oxygenators and comparing with experimental results 
using blood analogue fluids [33-35]. For example, 
Wickramasinghe et al. [33] have proposed mass-
transfer and friction-factor correlations for flat-sheet 
and hollow-fiber blood oxygenators. Generalized 
Graetz, Reynolds, and Schmidt numbers are used to 
account for the shear thinning behavior of blood. 
Because oxygen not only dissolves in plasma but also 
binds to hemoglobin, a mass-transfer enhancement 
factor based on film theory has been developed to 
account for this event. Experimental results for oxygen 
transfer to bovine blood and both non-Newtonian and 
Newtonian blood analogue fluids indicate that the 
correlations developed may be used to predict the 
performance of blood oxygenation. 
6. BIOARTIFICIAL LIVERS 
In a bioartificial liver (BAL) device, the patient 
plasma is circulated extracorporeally through a 
bioreactor that houses metabolically active liver cells 
(hepatocytes) sandwiched between artificial plates or 
capillaries (Figure 3). Several reviews are available on 
BAL devices, to present their current developments 
and future trends. For example, Strain and Neuberger 
[9] provided a state of the art of the BAL by focusing on 
the type of cell for a BAL bioreactor, clinical trials and 
trends. Pless and Sauer [10] summarized the current 
status of artificial liver assist devices such as 
hemodiafiltration, hemoperfusion, plasmapheresis, and 
hemodialysis, bioartificial liver assist devices and 
further development in BAL assist devices. Allen et al. 
[11] focused on advances in extracorporeal BAL 
devices, cellular components, stabilization of primary 
hepatocyte phenotype, bioreactor design, regulation 
and safety, and clinical trials.  
 
Figure 3: A bioartificial liver (BAL) bioreactor (redrawn from 
[9]).  
The liver has a number of important functions that 
are principally carried out by hepatocytes [9]. These 
cells synthesize many proteins, including clotting 
factors; they produce bile and regulate carbohydrate, 
fat, and protein metabolism; they detoxify the ammonia 
product of nitrogen metabolism and break down alcohol 
and drugs. In addition, the liver has Kupffer cells that 
are part of the immune system. The healthy liver is able 
to regenerate itself after acute injury, but once 
damaged by fibrosis and cirrhosis, caused by a variety 
of chronic conditions such as alcohol abuse or infection 
with hepatitis virus B or C, it can no longer regenerate 
normally [9]. Among currently available therapies, liver 
transplantation is an accepted and effective way for the 
treatment of acute hepatic failure. However, it is not 
applicable for many patients due to limited organ 
availability. Artificial liver systems have been developed 
to bridge patients with severe liver failure to liver 
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transplantation or liver regeneration. In the past two 
decades, several devices have been developed, which 
can be classified into two main categories: artificial 
organs, based on classical methods such as 
hemodialysis, plasmapheresis, specific or non-specific 
adsorption, and bioartificial organs. 
Artificial Organs 
To clear the blood of protein-bound substances 
such as bilirubin, bile acids, short chain fatty acids, and 
aromatic amino acids, with dialysis techniques, 
adsorbent or acceptor substances are necessary to 
enhance mass exchange. The molecular adsorbent 
recirculation system (MARS, Gambro Hospal GmbH, 
Germany) and the single pass albumin dialysis (SPAD) 
were introduced to improve removal of protein-bound 
substances [1, 10, 36]. In the MARS system, the 
albumin solution is circulated in a closed circuit 
separated from patient blood by a high-flux 
hemodialysis filter. The albumin acts as the acceptor 
for the toxins. It is partly regenerated by passing an 
anion exchanger and a charcoal adsorber in a closed 
circuit, which is itself dialyzed. The noncommercial 
technique SPAD uses standard renal replacement 
therapy machines without an additional perfusion pump 
system. The patient’s blood flows through a hollow fiber 
hemodiafilter, identical to that used in MARS. The other 
side of this membrane is cleaned with an albumin 
solution in counter directional flow, which is, instead of 
being regenerated as in MARS, discarded after passing 
the hemodiafilter. The Prometheus® system (Fresenius 
Medical Care AG, Germany) combines the fractionated 
plasma separation and adsorption (FPSA) method with 
high-flux hemodialysis of the blood in an extracorporeal 
detoxification system [36]. In the FPSA system, a 
specific albumin-permeable polysulfone membrane 
with a cut-off of approximately 250 kDalton is used. 
Thus albumin and the protein-bound toxins pass 
through the membrane and are then removed from the 
blood by an adsorber within the secondary circuit.  
Treatments with these non-biological liver systems 
have shown some benefits for short-term liver support 
in patients with acute liver failure. However, most of the 
clinical studies were conducted on a small number of 
patients and thus provided limited clinical data. 
Bioartificial Livers 
The principle of BAL devices is closer to that of a 
real liver and therefore these systems are expected to 
be more efficient than non-biological artificial organ. In 
a BAL device, the patient plasma is circulated 
extracorporeally through a bioreactor that houses 
metabolically active liver cells (hepatocytes) 
sandwiched between artificial plates or capillaries. The 
basic BAL bioreactor consists of a hollow-fiber 
membrane device [9]. Up to 1010 human or porcine 
hepatocytes are housed into the extracapillary space of 
the bioreactor either alone or attached to microcarrier 
beads. In the primary circuit, the patient is connected 
by venous catheters to a plasma separator. In the 
secondary circuit, the plasma is separated, warmed, 
oxygenated, and then perfused through the lumen of 
the bioreactor capillaries. This allows free exchange of 
molecules between hepatocytes and patient plasma: 
hepatocytes extract oxygen and nutrients and detoxify 
chemicals in the plasma, and their metabolites pass 
into the plasma. Blood cells are then added back to the 
plasma before it is returned to the patient. 
Several BAL devices have been proposed including 
the following ones [1, 10, 11]: 
• The extracorporeal liver assist device (ELAD, 
Vitagen) uses around 200 g of cells of the 
human hepatoblastoma cell line C3A (derived 
from HepG2) in modified dialysis devices. The 
cells are housed in the extracapillary space 
separated from plasma by the capillary 
membranes. Prior to entering the bioreactor, the 
plasma passes a charcoal adsorber and a 
membrane oxygenator. In a similar setting, the 
HepatAssist (Circe Biomedical) system uses 5 - 
7 109 cryopreserved porcine hepatocytes.  
• The modular extracorporeal liver support (MELS) 
system is based on the Cell Module, a unit 
consisting of 3 interwoven capillary bundles in a 
polyurethane housing. One of the bundles 
serves as decentralized oxygenation; 2 bundles 
are used for perfusion with patient plasma. It is 
operated with primary porcine hepatocytes or 
with human hepatocytes isolated from discarded 
donor organs. In the MELS system, the Cell 
Module is combined with SPAD and continuous 
veno-venous hemodiafiltration. 
• Within the BAL device developed by the 
Amsterdam Medical Center (AMC-BAL), the 
capillary membranes serve oxygenation, in 
contrast to previous systems. The cell 
compartment of the device is loaded with about 
200 g of primary porcine hepatocytes. During 
therapy, the polymeric matrix of the device is 
directly perfused by patient plasma. 
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These systems use various cell sources, having 
different advantages and limits [10]. Porcine 
hepatocytes are available in large quantities, but bear 
the risk of zoonoses (such as porcine endogenous 
retrovirus or herpes species) and metabolic 
incompatibility. Human tumor cell lines can be easily 
expanded to large quantities, but have the 
disadvantage of poor metabolic performance and 
potential metastatic ability. Primary human cells are 
biocompatible but are not available in large quantities 
and originate from histologically impaired organs. 
Various membranes are used which function as 
scaffold for cell attachment and as permselective 
barriers allowing transfer of oxygen and nutrients [1]. 
The hollow fiber membranes are made from different 
polymeric membranes, such as cellulose acetate in 
ELAD (MWCO 70 kDa) or polyethersulfone (molecular 
weight cut-off (MWCO)> 400,000) in MELS. Hydrophilic 
membranes are used for cell attachment and mass 
exchange, while oxygenation membrane capillaries are 
hydrophobic (e.g. polypropylene in AMC-BAL). Ideally, 
the semi-permeable membrane has a nominal MWCO 
that is high enough to allow diffusion of small 
molecules and proteins (e.g. albumin) but small enough 
to exclude cellular material, as well as immunoglobulins 
and viral pathogens. 
BAL devices have been tested in vitro and in animal 
models in several studies [9]. Different parameters 
have been measured as indicators of hepatocyte 
viability and function, including clotting factor 
production, urea synthesis, conjugation of the bile 
pigment bilirubin, drug metabolism, and a variety of 
other metabolic processes. The first clinical trial was 
realized in 1987 to treat a single patient with acute liver 
failure. Although the feasibility of BAL devices was 
easily established, the efficacy of the treatment was 
much more difficult to demonstrate with only few 
clinical trials performed. 
Further developments in BAL devices include 
finding an appropriate cell source [10]. Research on 
human hepatic progenitor cells, embryonic stem cells, 
or fetal stem cells might offer the necessary sources. In 
addition, the combination of artificial and bioartificial 
organ is a promising area. For example, the 
HepatAssist system (bioreactor + charcoal adsorber) 
and MELS (bioreactor + SPAD) combine bioreactors 
with detoxification techniques. 
7. BIOARTIFICIAL PANCREAS  
In a bioartificial pancreas, islets are encapsulated 
within a semi-permeable membrane and transplanted 
into a patient. The islets are isolated from the patient's 
immune system, whereas oxygen, glucose, and 
nutrients are supplied through the membrane. Insulin 
secreted by the islets in response to changes in blood 
glucose levels can diffuse from the bioartificial 
pancreas to the patient to maintain blood glucose 
metabolism. Kizilel et al. [12] reviewed the recent 
progresses and challenges remaining for the 
successful development of the bioartificial pancreas. 
The review focuses on historical development, 
impediments to the progress of cell encapsulation 
technology, different forms of bioartificial pancreas, and 
techniques in microencapsulation. Teramura and Iwata 
[13] focused on the principle of the bioartificial 
pancreas, conventional bioartificial pancreas (types of 
bioartificial pancreas, islet encapsulation with agarose 
beads, and clinical applications), and conformal coating 
of cell surfaces. 
Diabetes represents a major public health problem, 
as it is the most frequent endocrine disease in 
industrialized countries. In 2005, the number of people 
suffering from diabetes worldwide was 177 million, and 
this number is expected to double by the year 2025 
[12]. The complications of diabetes include several 
medical problems related to ophthalmic, renal, 
neurological, cerebrovascular, cardiovascular, and 
peripheral vascular disease. Type 1 diabetes (insulin-
dependent diabetes) occurs when pancreatic islet cells 
are unable to produce insulin. Consequently, the blood 
glucose concentration becomes high while tissues are 
starving for metabolic fuel. In Type 2 diabetes (non–
insulin-dependent diabetes), the body continues to 
make at least some insulin, but is unable to respond 
properly to the action of insulin produced by the 
pancreas. Nowadays, the treatment for Type 1 
diabetes include exogenous insulin with external 
glucose monitoring, whole-organ pancreas 
transplantation, islet cell transplantation, the artificial 
pancreas, and the bioartificial pancreas. Three major 
types of bioartificial pancreas have been developed: 
diffusion chamber, hollow fiber unit and microcapsules 
(Figure 4) [13]. 
The mechanical artificial pancreas consists of a 
glucose sensor, an insulin pump, and a computer, 
which determines the rate of insulin delivery [12]. In 
contrast, a bioartificial pancreas is a device that 
substitutes for the endocrine portion of the pancreas. It 
contains functional islets encapsulated within a 
semipermeable membrane to protect cells from the 
host immune response. In order to meet the 
requirement of immunoisolation, the membrane has to 
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reject antibodies, complements, some cytokines, and 
other cytotoxic substances. For islets survival, the 
membrane has to allow the free permeation of 
substances, such as oxygen, necessary nutrients, and 
cellular metabolites (Figure 5). 
In a diffusion chamber pancreas, Nuclepore™ 
membranes with a pore size of 0.05–1 µm are used as 
an immunoisolation membrane [13]. For example, 
Hirotani et al. [37] reported that normoglycemia was 
maintained for 30 weeks in streptozotocin (STZ)-
induced diabetic rats by implanting a device that 
encapsulated mice pancreatic beta cell lines (MIN6) 
(xenotransplantation). Recently, Lee et al. [38] reported 
human fetal pancreatic islet like cell clusters (18–24 
weeks) enclosed in devices (TheraCyte) made of 
polytetrafluorethylene (PTFE) with a pore size of 0.4 
µm that were transplanted at a subcutaneous site. After 
transplantation into in the non-obese diabetic mouse 
model of type 1 diabetes, the blood glucose level was 
normalized, indicating efficacy. A limit of the diffusion 
chamber devices is the aggregation of islets in the 
space [13]. When islets form aggregates, cells in the 
center are necrotic due to oxygen shortage. In addition, 
the size of the device (evaluated to 30 cm in diameter) 
would be a major obstacle when applied to patients. 
Hollow fiber and tubular membranes have been 
extensively studied in bioartificial pancreas. In one of 
the first studies, Maki et al. [39] developed a bioartificial 
pancreas that was suitable for implantation into large 
animals. The device consisted of a chamber passing a 
semi-permeable tubular membrane that was connected 
to vascular grafts. Islets were placed between the 
 
Figure 4: The conventional bioartificial pancreas types. (a) microcapsule, (b) diffusion chamber, and (c) hollow fiber-based 
diffusion chamber (redrawn from [13]). 
 
Figure 5: Concept of the immunoisolation membrane in a bioartificial pancreas (redrawn from [13]). 
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housing chamber and the tubular membrane (MWCO 
80 kDa). The device was implanted in severely diabetic 
dogs that had undergone total pancreatectomies. 
Aspirin was systematically administered in order to 
control blood coagulation and inhibit thrombus 
formation, which could not be applicable in a clinical 
treatment due to the increase risk of bleeding. In 
addition, such devices have poor diffusive exchange 
between the enclosed islets and surrounding blood and 
are vulnerable to rupture, which have limited their 
application. 
In order to improve these devices, recent studies on 
bioartificial pancreas focused on evaluation of new 
membrane materials. For example, Risbud et al. [40] 
investigated the in vitro biocompatibility and suitability 
of cellulose dialysis membrane (Spectra/Port 2, MW no 
larger than 12–14000) for the immunoisolation of 
pancreatic islets. The membrane allowed regulated 
transport of glucose and insulin in an in vitro diffusion 
assay. These islets also retained their functionality, as 
judged by insulin secretion. New configurations have 
also been proposed. For example, Ikeda et al. [41] 
developed a new type of bioartificial pancreas 
composed of polyethylene vinyl alcohol (EVAL) hollow 
fibers that were permeable to glucose and insulin and a 
poly-amino-urethane-coated, non-woven PTFE fabric 
that allowed cell adhesion. Porcine islets attached to 
the surface of the PTFE fabric, but not to the surface of 
the EVAL hollow fibers, allowing nutrient and oxygen 
exchange between blood flowing inside the fibers and 
cells outside. The bioartificial pancreas was inoculated 
with porcine islets and connected it to the circulation of 
totally pancreatectomized diabetic pigs. Blood glucose 
levels were found to be reduced to a normal range and 
general health was improved, resulting in longer 
survival times. In addition, regulation of insulin 
secretion from the bioartificial pancreas was controlled 
in response to glucose both in vitro and in vivo. 
Moreover, improved mathematical models of local 
oxygen transport have been developed. Dulong and 
Legallais [42] calculated the number of islets that 
needed to be implanted in order to obtain a correct 
response in terms of insulin secretion. In most 
configurations, it was found to be much higher than that 
of ultimately functional islets, because of hypoxia and 
necrosis. Fiber length should thus be adjusted 
accordingly. The authors concluded that the 
compromise to be found between the reduction of the 
number of implanted islets and fiber length and 
diameter did not correspond to realistic hollow fiber 
systems.  
8. DRUG DELIVERY USING MEMBRANES 
Drug delivery devices based on membranes consist 
basically of osmotic and diffusion controlled membrane 
systems [1, 2]. Stamatialis et al. [1] reviewed in details 
several aspects of drug delivery systems including 
osmotic membrane systems, diffusion controlled 
membrane systems (pills, implants and patches), 
transdermal drug delivery, passive diffusion, 
iontophoresis, etc. Membrane based formulations used 
in drug delivery consist of colloids like liposomes and 
nanocapsules. Liposomes are enclosed spherical 
vesicles with one or several concentric phospholipidic 
membrane bilayers with an aqueous phase inside. A 
large number of reviews focus on liposomes do to their 
widespread used in fields like pharmaceutics, 
cosmetics and foods e.g. [14-16]. Laouini et al. [15] 
reviewed the recent progresses in liposomal drug 
delivery systems including definition and classification 
of liposomes, methods of preparation, characterization, 
and pharmaceutical, cosmetic and food applications. 
Nanocapsules are other membrane based drug 
delivery systems. Nanocapsules have a polymeric shell 
membrane and an inner liquid core, the drug being 
dissolved in the inner core, or adsorbed at their 
surface. Several reviews e.g. [17, 18] are available on 
drug loaded nanoparticles, including nanocapsules to 
present the state on the art on preparation methods 
and applications in drug delivery. 
A drug delivery system is a device or a formulation 
that enables the introduction of a therapeutic substance 
in the body and improves its efficacy and safety by 
controlling the rate, time, and place of its release [43]. It 
includes the administration of the therapeutic product, 
the release of the active ingredients by the product, 
and the subsequent transport of the active ingredients 
across the biological membranes to the site of action. A 
drug delivery system may be: (1) a device used to 
deliver the drug, or (2) a formulation of the drug which 
will be administered for a therapeutic purpose. Drugs 
may be introduced into the human body by various 
anatomical routes. The choice of the route of 
administration depends on the disease, the effect 
desired, and the product available. Drugs may be 
administered directly to the organ affected by disease 
or given systemically and targeted to the organ. 
Methods of systemic drug delivery are classified as 
follows: gastrointestinal system (oral, rectal), 
parenteral, transnasal, pulmonary (drug delivery by 
inhalation), transdermal drug delivery and intra-
osseous infusion. The oral route of drug administration 
is the most used for both conventional as well as novel 
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drug delivery. The reasons for this preference are the 
ease of administration and widespread acceptance by 
patients.  
Drug Delivery Systems Using Membranes  
Membrane devices used to deliver the drug consist 
basically of a drug reservoir [1]. Two main types of 
systems can be distinguished: (1) osmotic membrane 
systems (Figure 6), and (2) diffusion controlled 
membrane systems. An osmotic system consists of a 
reservoir made of a polymeric membrane permeable to 
water but not to the drug (semi-permeable membrane). 
The reservoir contains a concentrated drug solution. As 
water crosses the membrane due to osmotic pressure, 
the drug solution is released through the orifice. In 
diffusion controlled membrane systems, the drug 
release is controlled by transport of the drug across a 
membrane. The transport is dependent on the drug 
diffusivity through the membrane and the thickness of 
the membrane. These systems find broad application in 
pills, implants and patches. 
 
Figure 6: Schematic view of an osmotic drug delivery system 
(redrawn from [1]). 
Drug delivery membrane systems include osmotic 
membrane systems, diffusion controlled membrane 
systems (pills, implants, patches), transdermal drug 
delivery (passive diffusion, iontophoresis and skin or 
device controlled delivery) [2]. These drug delivery 
applications concern mainly transdermal, oral and 
ocular delivery routes of administration. 
In transdermal drug delivery [1], the drug is 
incorporated into a patch and delivered through the 
skin due to the concentration difference or electrical 
current (Figure 7). Transdermal patches are used as a 
convenient and effective method of drug delivery 
through the human skin. A membrane may exclusively 
control or partially control drug transport together with 
other components (such as the adhesive layer). 
Patches are commercialized for example for delivery of 
nicotine for smoking cessation, estrogenor testosterone 
for hormonal therapy, and methylphenidate for 
attention deficit hyperactivity disorder. Ocular patches 
are membrane-controlled reservoir systems. The drug, 
accompanied by carriers, is captured in a thin layer 
between two transparent, polymer membranes, which 
control the rate of drug release. The device is placed 
on the eye where it floats on the tear film. The drug 
slowly diffuses to the target area. 
 
Figure 7: Schematic view of transdermal membrane delivery 
systems (redrawn from [1]). 
As a non-invasive transdermal drug delivery 
method, iontophoresis applies electrical current to 
deliver drugs through the skin to the underlying tissue 
or capillaries and then to the whole circulating system 
[44]. A voltage applied between two electrodes 
immersed in a drug solution causes the drug to be 
moved from the donor part into the skin. The positively 
charged electrode (anode) attracts the negatively 
charged drug ions; the negatively charged electrode 
(cathode) attracts the positively charged ions. These 
devices are commercialized for example for delivery of 
lidocaine and epinephrine in local analgesia.  
In oral delivery, the drug is pressed into tablet which 
is coated with a non-digestible hydrophilic membrane 
such as cellulose esters like cellulose acetate, cellulose 
acetate butyrate, cellulose triacetate and ethyl cellulose 
[1, 2, 45]. Once the membrane gets hydrated, a 
viscous gel barrier is formed, through which the drug 
slowly diffuses. The release rate of the drug is 
determined by the type of membrane used. The key 
feature of these systems is that drug release is 
independent of pH and hydrodynamics of the external 
dissolution medium. The result is a robust dosage form 
for which the in vivo rate of drug release is comparable 
to the in vitro rate, producing an excellent in vitro/in 
vivo correlation. Another key advantage is that they are 
applicable to drugs with a broad range of aqueous 
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solubility such as diltiazem HCl, carbamazepine, 
metoprolol, oxprenolol, nifedipine, and glipizide. 
Another example is implants which consist of a 
membrane reservoir containing a drug in liquid or 
powder form [2]. The drug slowly diffuses through the 
nondegradable membrane that usually consists of 
silicone and ethylene-co-vinyl acetate. By properly 
choosing membrane thickness and permeability, 
release kinetics can be controlled and designed for a 
specific therapeutic target. For example, an implantable 
5 years contraceptive permits the long term release of 
levonorgesterol. 
Membrane Based Formulations 
Membrane based formulations used to deliver the 
drug consist of carriers that are biodegradable, 
biocompatible, targeting, and stimulus responsive like 
liposomes and nanocapsules [45]. Liposomes are 
enclosed spherical vesicles that are organized in one 
or several concentric phospholipidic membrane 
bilayers with an aqueous phase inside. Liposomes are 
usually classified on the basis of their size (small, large 
and giant vesicles), number of bilayers (uni-, oligo and 
multi-lamellar) and phospholipid charge (neutral, 
anionic or cationic). Liposomes have also been 
categorized with respect to their function such as 
conventional, stealth, ligand-targeted, long-release, 
and triggered-release.  
Liposomes can entrap hydrophilic pharmaceutical 
agents in their internal aqueous compartment and 
lipophilic drugs within the lipid membrane. Over the 
past few years, liposomal drug preparations have been 
developed from laboratory research to clinical 
applications, such as Doxil, Myocet and DepoCyt [16]. 
Not only the pharmaceutical area benefits from 
liposomes, but also the food and cosmetic industries. 
Liposome function is strongly dependent on properties 
such as liposome size, shape, lamellarity and surface 
charge. Other parameters that characterize liposomes 
are the encapsulation efficiency, the ratio of phospho- 
lipids to drug concentration, the surface charge through 
zeta potential measurement, phase transitions through 
differential scanning calorimetry and quantification of 
residual solvents through gas chromatography.  
Since the pioneering discovery of liposomes by 
Bangham et al. [46], many techniques have been 
reported for liposome preparation including mechanical 
methods (preparation by film methods, homogenization 
techniques such as sonication, microfluidization, 
extrusion), methods based on replacement of organic 
solvents by aqueous media (ethanol injection method, 
proliposome-liposome method, reverse-phase 
evaporation), and methods based on detergent 
removal [14]. The ethanol injection method is an 
interesting technique for production of liposomes. It 
offers several advantages, e.g., simplicity, fast 
implementation, and reproducibility. The ethanol 
injection method was first reported in the early 1970s 
by Batzri and Korn [47] as one of the first alternatives 
for the preparation of small unilamellar vesicles (SUVs) 
without sonication. By the immediate dilution of the 
ethanol in the aqueous phase, the lipid molecules 
precipitate and form bilayer planar fragments [48]. 
Through energy dissipation in the system (by stirring 
and/or ultrasonication), the fragments of these lipid 
bilayers tend to decrease the exposure of the 
hydrophobic parts of their molecules to the aqueous 
environment, resulting in the curvature of these 
fragments which take a quasi-spherical structure. 
Liposomes with modified surfaces have also been 
developed using several molecules, such as 
glycolipids, or the synthetic polymer polyethylene glycol 
(PEG) [49]. The presence of PEG on the surface of the 
liposome has been shown to extend blood-circulation 
time while reducing mononuclear phagocyte system 
uptake (stealth liposomes). PEG modified liposomes 
have then been developed for encapsulation of active 
molecules, with high target efficiency and activity. In 
addition, by modification of the terminal PEG molecule, 
liposomes can be actively targeted with monoclonal 
antibodies or ligands. 
Nanocapsules are also membrane based formula- 
tions used in drug delivery. They are ranging in size 
from about 10 to 1000 nm. Nanocapsules have a 
polymeric shell membrane and an inner liquid core, the 
drugs being dissolved in the inner core, or adsorbed at 
their surface. Nanocapsules differ from nanospheres 
that have a matrix type structure with drugs adsorbed 
at their surface, entrapped in the particle or dissolved in 
it. Nanocapsules have been investigated for the 
entrapment of a wide variety of drugs, for applications 
ranging from ophthalmic delivery to carriers in 
chemotherapy. They are characterized in terms of 
morphology (transmission electron microscopy and 
scanning electron microscopy), size and size 
distribution (i.e. by photon correlation spectroscopy), 
zeta potential and density (i.e. by isopycnic 
centrifugation) [18]. Important properties of 
nanocapsules are their drug entrapment efficacy 
(amount of drug loaded in the nanocapsules expressed 
as the percentage of the total amount of drug added in 
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the process), and their drug release behaviour (in vitro 
and in vivo) [18].  
Several methods for the preparation of 
nanocapsules are available, involving either a 
dispersion of preformed polymers or a polymerization 
of dispersed monomers [17]. Nanocapsules prepared 
by dispersion of preformed polymers involve the use of 
purified natural molecules or preformed synthetic 
polymers, and for nanocapsules prepared by 
polymerization reaction the following polymers may be 
useed: polyacrylamide, poly(alkyl methacrylates), 
poly(alkyl cyanoacrylates) and polyglutaraldehyde. The 
nanoprecipitation method developed by Fessi et al. [50] 
is an easy and reproducible method involving 
dispersion of preformed polymers. It is based on the 
interfacial deposition of a polymer following 
displacement of a semi-polar solvent miscible with 
water from a lipophilic solution. The organic phase 
(solvent, polymer, eventually oil, and drug) is added 
drop wise under moderate stirring into the aqueous 
phase (water, and surfactant). Another method to 
prepare nanocapsules is the interfacial polymerization 
technique in which two monomers, one oil-soluble and 
the other water soluble, are employed and a polymer is 
formed on the droplet surface [18]. The organic phase 
(solvent, monomer, eventually oil, and drug) is added 
into the aqueous phase (water, co-monomer and 
surfactant). 
CONCLUSION 
Membrane based techniques are extensively used 
for biomedical applications. Current techniques include 
dialysis and blood oxygenation used in daily 
treatments. Applications of artificial liver and bioartificial 
pancreas are more limited and clinical trials are still 
under way. Drug delivery using membrane based 
systems like liposomes and nanocapsules has been 
increasingly reported with commercial products now 
available in particular for cancer treatment. All these 
membrane techniques involve a large range of 
polymeric or inorganic membranes, at very large scales 
(e.g. dialysis and blood oxygenation) or at very small 
scales (e.g. the membrane surrounding the liposomes 
or nanocapsules), in flat sheet or hollow fiber 
configurations. Different mechanisms of transfer are 
associated to these processes like molecules diffusion 
(e.g. in dialysis and drug delivery devices) or 
convection (e.g. in hemofiltration), in the liquid phase 
(e.g. in dialysis, hemofiltration, etc) or gas phase (e.g. 
in blood oxygenation). Further developments are 
related to membrane materials with improved 
biocompatibility and mass transfer (e.g. in bioartificial 
pancreas), new biological developments (e.g. new cell 
sources for BAL devices), device and process design 
(e.g. in dialysis and BAL devices), characterization and 
modelling of the systems, and intensive clinical trials 
based on appropriate and well controlled 
methodologies. 
ABBREVIATIONS 
BAL: bioartificial liver  
DFPP: double-filtration plasmapheresis  
EVAL:polyethylene vinyl alcohol  
FPSA: fractionated plasma separation and adsorption  
HCl: hydrochloric acid 
hMSCs: human mesenchymal stem cells  
HSCs: hematopoietic stem cells  
IgA: immunoglobulin A  
IgG: immunoglobulin G  
IgM: immunoglobulin M 
LDL: low density lipoprotein  
LPS: lipopolysaccharide 
MELS: modular extracorporeal liver support  
MW: molecular weight  
MWCO: molecular weight cut-off 
PEG: polyethylene glycol  
PTFE: polytetrafluorethylene  
PVDF: polyvinylidene fluoride  
STZ: streptozotocin  
TMP: transmembrane pressure  
SYMBOLS 
C: concentration (mg/mL) 
C0 and Ct: initial and final solute concentrations at 
the beginning and end of each dialysis (mg/mL) 
G: generation rate (mg/min) 
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Kd: intermittent dialyzer clearance (mL/min) 
Kr: continuous renal clearance (mL/min) 
t: time (min) 
V: solute distribution volume (L) 
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